JNJ vs SRNE · P/E 17, rev $49.37B vs $385.9K cap
Johnson & Johnson (JNJ) versus Sorrento Therape (SRNE) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Sorrento Therape (SRNE) is a biotechnology company listed on OTCQB.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
SRNE does not have a complete income-statement cache yet.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. SRNE currently screens at market cap $385.9K.
Not investment advice. Open the JNJ and SRNE stock pages for the full models.
Not investment advice.